Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimoclomol in ALS (ORARIALS-01)
NCT03491462Phase 3Completed
- Sponsor
- Zevra Therapeutics
- Start
- Jul 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Arimoclomol with Placebo (2 arms). Primary endpoint: Combined Assessment of Function and Survival at 76 weeks. Started Jul 2018; status: completed.
02
Drugs
arimoclomol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03491462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491462.